波罗样酶1 (PLK1) 是一种在皮细胞中的新型CARD14结合蛋白
Styliani Iliaki1, Marja Kreike1, Natalia Ferreras Moreno2
1Center for Inflammation Research, Unit of Molecular Signal Transduction in Inflammation, VIB, B-9052 Ghent, Belgium; Department of Biomedical Molecular Biology, Ghent University, B-9052 Ghent, Belgium.
Biochemical pharmacology
|May 26, 2024
概括
波罗样酶1 (PLK1) 与CARD14结合,这是一个涉及皮肤炎症疾病 (如牛皮) 的蛋白质. 破坏这种相互作用会增强CARD14信号传输,这表明PLK1对这种通路进行负面调节.
科学领域:
- 免疫学 免疫学 免疫学
- 细胞生物学 细胞生物学
- 皮肤病学 皮肤病学
背景情况:
- 含有卡斯巴酶招募域 (CARD) 的蛋白质14 (CARD14) 对于NF-κB信号传递和皮肤角质细胞中的炎症基因表达至关重要.
- 过度激活的CARD14突变与炎症性皮肤疾病有关,包括牛皮.
- 对于CARD14信号的上游监管仍然不太了解.
研究的目的:
- 确定新的CARD14结合蛋白并阐明它们在调节CARD14信号传递中的作用.
- 为了研究CARD14和波罗类激酶1 (PLK1) 之间的相互作用.
主要方法:
- 与质谱学 (AP-MS) 相结合的无偏亲和净化被用于选CARD14结合蛋白.
- 描述了CARD14和PLK1之间的结合相互作用.
- 评估了PLK1结合对CARD14信号传递的功能影响,使用人类角质细胞中与牛皮相关的CARD14变体.
主要成果:
- 波罗样酶1 (PLK1) 被确定为一种新的CARD14结合蛋白.
- CARD14-PLK1结合发生在CARD14链接区域的依赖基因上,并且独立于CARD14 CARD域.
- 在与牛皮相关的CARD14变体 (CARD14(E138A)) 中,PLK1结合基因的破坏导致了CARD14诱导的炎症信号和基因表达的增加.
结论:
- PLK1是CARD14介导的炎症信号传递的新型负调节剂.
- 了解CARD14-PLK1相互作用可能为炎症性皮肤疾病提供新的治疗点.
相关概念视频
Cytoskeletal Linker Proteins - Plakins
2.3K
Plakins are large proteins with binding domains for microtubules, microfilaments, intermediate filaments, and membrane-associated protein complexes at cell junctions. Plakin functions are evolutionarily conserved and are primarily involved in organizing the different components of the cytoskeleton by crosslinking them to each other and connecting them to the cell-matrix and cell adhesion complexes. They are also known to interact with signal transducers, serve as scaffolds for signaling...
2.3K
PI3K/mTOR/AKT Signaling Pathway
3.5K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.5K
M-Cdk Drives Transition Into Mitosis
5.6K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.6K
Receptor Tyrosine Kinases
12.7K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
12.7K
MAPK Signaling Cascades
5.4K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.4K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K


